Nanobiotix S.A. — 6-K Filing
🧾 What This Document Is
This is a standard regulatory filing from Nanobiotix (NBTX). It’s not an earnings report or a press release about a big discovery—it’s a required, routine update to inform the market about the company's share structure and voting power as of March 31, 2026.
👉 Why it matters: Think of this as a public company's official "headcount" of its owners and their voting strength. It ensures transparency for all investors.
🏢 What The Company Does
In simple terms, Nanobiotix is a medical tech pioneer. They use nanotechnology (think incredibly tiny particles) to develop new treatments, primarily for cancer. Their goal is to use physics, not just biology, to change how therapies work in the body.
👉 Why it matters: They're a clinical-stage company, meaning their tech is still being tested in patients. It's innovative but also carries the risk typical of cutting-edge biotech.
📊 The Voting & Ownership Breakdown
This is the core data of the filing, reported as of March 31, 2026.
| Metric | Number |
|---|---|
| Shares Outstanding | 48,517,630 |
| Total Theoretical Voting Rights | 50,165,132 |
| Total Exercisable Voting Rights | 50,143,014 |
Understanding the Numbers:
- Shares Outstanding: The total pieces of the company owned by investors.
- Theoretical Voting Rights: This higher number includes shares whose voting rights are temporarily suspended (like shares held by the company itself). It's used to calculate regulatory thresholds.
- Exercisable Voting Rights: The "real-world" votes that can be cast at a shareholder meeting. It excludes shares held in the company's treasury.
👉 Why it matters: The small gap between theoretical and exercisable votes (about 22,000 votes) suggests the company holds very few treasury shares. This means the voting power is almost fully in the hands of external shareholders.
⚖️ Why This Filing Exists (The Rules)
This isn't optional. French law (Article L.233-8 II) and the rules of the French financial regulator (AMF) require companies listed in France to publish this data monthly. It keeps the market fair and informed.
👉 Why it matters: It prevents hidden changes in control. If a big investor bought a chunk of shares, everyone would see the voting rights shift in these regular updates.
🔍 Context & Company Background
- Founded: 2003
- Listed: On Euronext Paris since 2012 and on the Nasdaq in New York since December 2020.
- Tech: They own over 30 patent families across three nanotechnology platforms focused on oncology (cancer), drug delivery, and brain disorders.
- Global Presence: Headquartered in Paris, with a key subsidiary in Cambridge, Massachusetts, a major biotech hub.
💡 What This Signals About Nanobiotix
👍 Strength: It's a fully reporting, dual-listed company (France & U.S.), which means it adheres to high transparency standards. The regular filing shows operational discipline.
⚠️ Risk/Context: As a late-stage clinical biotech, its value is tied to research and drug trial outcomes, not yet to sales or profits. This filing is about structure, not financial health.
📅 Key Contact Information
For questions, the company directs inquiries to:
- Communications (US): Brandon Owens, +1 (617) 852-4835, [email protected]
- Investor Relations (US): Joanne Choi, +1 (713) 609-3150
- Investor Relations (EU): Ricky Bhajun, [email protected]
- Media (France): Caroline Hardy, +33 06 70 33 49 50, [email protected]
- Global Media: Becky Lauer (uncapped), +1 (646) 286-0057, [email protected]
🧠 The Analogy
This filing is like the official roll call taken before a big school assembly. It doesn't tell you what the assembly will discuss (that's earnings or trial results), but it meticulously records how many students are present (shares) and who has a vote (voting rights) to ensure any decisions made are fair and legitimate.
🧩 Final Takeaway
This is a routine but essential governance snapshot showing Nanobiotix had ~48.5 million shares with ~50.1 million exercisable votes as of March's end. It confirms the company is following listing rules, and its voting power is widely distributed among shareholders, which is typical for a publicly traded biotech.